Hemophagocytic lymphohistiocytosis (HLH) is a fatal systemic inflammatory syndrome. HLH
has been reported as a rare immune-related adverse event (irAE) in patients receiving …

Immune homeostasis is maintained by an adequate balance of myeloid and lymphoid
responses. In chronic inflammatory states, including cancer, this balance is lost due to …

Background: Acquired hemophagocytic lymphohistiocytosis (HLH) is a rare but potentially
fatal condition characterized by hyperactivation of macrophages and cytotoxic lymphocytes …

Background Programmed cell death protein 1 (PD-1) checkpoint inhibitors such as
pembrolizumab are novel therapeutics used to treat various advanced malignancies …

Immunotherapy has dramatically changed the therapeutic landscape of oncology, and has
become standard of care in multiple cancer types in front or late lines of therapy, with some …

Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint
inhibitors: case report and systematic review of the literature - PMC Back to Top Skip to …

Auto-immune hemolytic anemia (AIHA) and hemophagocytic lymphohistiocytosis (HLH) are
both rare immune-related adverse events (irAEs) following treatment with immune …

A woman with metastatic melanoma was treated with immunotherapy induction with
ipilimumab and nivolumab and radiotherapy to liver metastases. The patient deteriorated …

Background Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening state
of immune hyperactivation. It has the highest mortality rate among all hematological immune …

Immune checkpoint inhibitors have significantly improved the prognosis of melanoma
patients. However, these therapies may trigger unexpected immune-related adverse events …